Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.

Original publication

DOI

10.1016/S2352-3026(20)30205-2

Type

Journal article

Journal

Lancet Haematol

Publication Date

08/2020

Volume

7

Pages

e601 - e612

Keywords

Adult, Betacoronavirus, COVID-19, Coronavirus Infections, Disease Management, Expert Testimony, Humans, Infection Control, Leukemia, Myeloproliferative Disorders, Pandemics, Pneumonia, Viral, Practice Guidelines as Topic, Resource Allocation, SARS-CoV-2